Published in:
Open Access
01-12-2023 | Meningitis | Research
Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
Authors:
Oguz Resat Sipahi, Deniz Akyol, Bahar Ormen, Gonul Cicek-Senturk, Sinan Mermer, Ugur Onal, Fatma Amer, Maysaa Abdallah Saed, Kevser Ozdemir, Elif Tukenmez-Tigen, Nefise Oztoprak, Ummugulsum Altin, Behice Kurtaran, Corneliu Petru Popescu, Mustafa Sakci, Bedia Mutay Suntur, Vikas Gautam, Megha Sharma, Safak Kaya, Eren Fatma Akcil, Selcuk Kaya, Tuba Turunc, Pınar Ergen, Ozlem Kandemir, Salih Cesur, Selin Bardak-Ozcem, Erkin Ozgiray, Taskın Yurtseven, Huseyin Aytac Erdem, Hilal Sipahi, Bilgin Arda, Hüsnü Pullukcu, Meltem Tasbakan, Tansu Yamazhan, Sohret Aydemir, Sercan Ulusoy
Published in:
BMC Infectious Diseases
|
Issue 1/2023
Login to get access
Abstract
Background
Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM).
Materials/methods
This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018.
Results
Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3–5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34).
Conclusions
Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.